'The treatment paradigm for relapsed/refractory chronic lymphocytic leukemia (CLL) is slowly expanding, with clinical trials starting and a new generation of drugs being ushered in, says Susan M. O'Brien, MD.
In an interview with OncLive, O’Brien, MD, hematologist, oncologist, UC Irvine Health Chao Family Comprehensive Cancer Center, discusses upcoming novel treatments in relapsed/refractory CLL, such as the next generation of inhibition with BTK, SYK, and PI3K, as well as the outcomes of the recent RESONATE-2 trial.'
OncLive interview with Dr O'Brien:
global.onclive.com/web-excl...
Drugs mentioned:
ibrutinib (Imbruvica)
idelalisib (Zydelig)
duvelisib in trial versus ofatumumab (Arzerra)
TGR-1202 (PI3K inhibitor)
acalabrutinib, (ACP-196) a next-generation BTK inhibitor
Thoughts on RESONATE-2 data chlorambucil with ibrutinib in patients 65 years or older)
Neil
Photo: White eared honeyeater
Neil
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
CAR-T for CLL Hits Goal of Mid-Stage Trial - All patients had progressed on BTK inhibitors & most had failed venetoclax - MedPageToday, 6/12
News about V+O and Acalabrutinib from EHA
Re: Epcoritimab Trial
